# OnCo record muscle-invasive-bladder-cancer (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/muscle-invasive-bladder-cancer/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "muscle-invasive-bladder-cancer" ;
  schema:name "Muscle-invasive and advanced bladder cancer"@en ;
  schema:alternateName "MIBC"@en, "Invasive urothelial carcinoma"@en, "Metastatic urothelial carcinoma"@en ;
  schema:description "Once bladder cancer has grown into the muscle it needs more than scraping out: chemotherapy then removal of the bladder, or chemoradiation to keep it. For cancer that has spread, the antibody-drug conjugate enfortumab vedotin with pembrolizumab has replaced platinum chemotherapy as the first treatment."@en ;
  schema:url <https://onco.cc/cancers/muscle-invasive-bladder-cancer/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Bladder_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/Bladder_cancer> ;
  onco:tag "subtype-page" ;
  onco:related <https://onco.cc/cancers/non-muscle-invasive-bladder-cancer/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-niagara-nejm-2024/>, <https://onco.cc/key-papers/paper-ev-302-nejm-2024/>, <https://onco.cc/key-papers/paper-swog-8710-neoadjuvant-mvac-nejm-2003/>, <https://onco.cc/key-papers/paper-javelin-bladder-100-nejm-2020/> ;
  onco:pipeline <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/erdafitinib/>, <https://onco.cc/drugs/enfortumab-vedotin/> ;
  onco:standardOfCare <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/trials/niagara/>, <https://onco.cc/terms/cystectomy/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/trials/checkmate-274/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/radiosensitisers/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/enfortumab-vedotin/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/ev-302/>, <https://onco.cc/drugs/erdafitinib/>, <https://onco.cc/targets/fgfr3-receptor/>, <https://onco.cc/drugs/enfortumab-vedotin/> .